The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2018 | Results of the OPTIMISMM study for R/R multiple myeloma
Paul Richardson, MD, from Dana-Farber Cancer Institute, Boston, MA, discusses the exciting results of the Phase III OPTIMISMM trial (NCT01734928) that he presented at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL. The aims of this trial were to investigate the tolerability and efficacy of the three-drug combination of pomalidomide, bortezomib and dexamethasone compared to the combination of bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma (MM) in patients who had previously received lenalidomide therapy. Prof. Richardson then speaks about the next steps to further improve this treatment regimen.
